
ACTIVATE VLU Healing with Apligraf[®] and **TRANSFORM** the Wound Environment^{1,2}

A GUIDE to Application, Reassessment, and Reapplication*


Treatment of VLUs Starts with Good Wound Care, Including Compression and BBWM™



[†] VLUs are known to contain biofilm^{6,7,8}

[‡] Literature indicates that surface area reduction at 4 weeks is a good prognostic indicator to determine if an intervention is working.

Easy Application for VLUs



* For complete directions for use, please refer to the Apligraf package insert.

¹ Photo courtesy of Antonio J. Carrasco, PhD, MD

THE BIOTECH HEALER

Organogenesis

Empowering you to optimize VLU outcomes

VLU = Venous Leg Ulcer

ACTIVATE VLU Healing with Apligraf




Organogenesis_{inc.}

Weekly Follow Up Helps Optimize VLU Healing^{11,12}



Reassessment and Reapplication



^a The safety and effectiveness of Apligraf have not been established for patients receiving greater than 5 device applications. In the pivotal trial, patients received up to 5 applications over 3 weeks. The average number of applications per VLU patient was 3.3.^{11,12}

- Apligraf transmits potent healing signals and **CONVERTS** the wound from a chronic to an acute state^{1,2,13-15}
- Apligraf is the ONLY product FDA-approved to heal VLUs¹¹
- Apligraf CLOSES more VLUs, faster—as proven in a randomized controlled clinical trial and in real-word comparative effectiveness analyses^{11,12,16,17}

To order Apligraf or for more information, call 1.888.HEAL.2.DAY (1.888.432.5232)

Please refer to the Apligraf full prescribing information. References: 1. Stone RC, Stojadinovic O, Rosa AM, et al. A bioengineered living cell construct activates an acute wound healing response in venous leg ulcers. *Sci Transl Med.* 2017;9(371): eaa8611. doi:10.1126/scitranslmed.aaf8611. 2. Stone RC, Stojadinovic O, Sawaya AP, Rosa AM, Badiavas E, Blumenberg M, Tomic-Canic M. Treatment of chronic venous leg ulcers with bioengineered living cell construct induces Metallothioneins and MMP8 to resolve matrix fibrosis and reactivates healthy remodeling response. Abstract presented at SAWC SPRING/WHS (2016). 3. Carpenter S, David S, Fitzgerald R, et al. Expert recommendations for optimizing outcomes in the management of biofilm to promote healing of chronic wounds. *Wounds.*. 2016;28 (6 Suppl):S1-S20. 4. Schultz GS, Sibbald RG, Falanga V, et al. Wound bed preparation: a systematic approach to wound management. *Wound Repair Regen.* 2003;11 (Suppl 1):1-28. 5. Robson MC, Cooper DM, Aslam R, et al. Guidelines for the treatment of venous ulcers. *Wound Repair Regen.* 2017;26(1):20-25. 7. Fazil M, Bjarnsholt T, Kirketerp-Møller K et al. Quantitative analysis of the cellular inflammatory response against biofilm bacteria in chronic wounds. *Wound Repair Regen.* 2011;19: 3, 387–391. 8. Honorato-Sampaio K, Guees AC, Lima VL, Borges EL. Bacterial biofilm in chronic venous ulcer. *Braz J Infect Dis.* 2014;18: 3, 350–351. 9. Gelfand JM, Hoffstad O, Margolis DJ. Surrogate endpoints for the treatment of venous leg ulcers. *J Invest Dermatol.* 2002;119(6):1420–1425. 10. Phillips TJ, Machado F, Trout R, Porter J, Olin J, Falanga V. Prognostic indicators in venous ulcers. *J Am Acad Dermatol.* 2000;43(4):627-630. 11. Apligraf® [package insert]. Canton, MA: Organogenesis Inc. 2017. 12. Data on file. Organogenesis Inc. 13. Milstone LM, Asgari MM, Schwartz PM, Hardin-Young J. Growth factor expression, healing, and structural characteristics of Graftskin (Apligraf®). *Wounds.* 2000;112(5 Suppl A):12A-13Haaga V, Isaacs C,

©2018 Organogenesis Inc. OI-A1261 All rights reserved. Printed in U.S.A. 5/18 Apligraf is a registered trademark of Novartis

www.organogenesis.com